Cargando…
ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy
The deoxyribonucleic acid (DNA) repair gene encoding the excision-repair cross-complementation group 1 (ERCC1) protein is known to predict the response to platinum-based chemotherapy. Our aim was to explore whether ERCC1 expression predicted tumor response and survival in patients with recurrent or...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758255/ https://www.ncbi.nlm.nih.gov/pubmed/29390553 http://dx.doi.org/10.1097/MD.0000000000009402 |
_version_ | 1783290976065814528 |
---|---|
author | Ryu, Hyewon Song, Ik-Chan Choi, Yoon-Seok Yun, Hwan-Jung Jo, Deog-Yeon Kim, Jin Man Ko, Young Bok Lee, Hyo Jin |
author_facet | Ryu, Hyewon Song, Ik-Chan Choi, Yoon-Seok Yun, Hwan-Jung Jo, Deog-Yeon Kim, Jin Man Ko, Young Bok Lee, Hyo Jin |
author_sort | Ryu, Hyewon |
collection | PubMed |
description | The deoxyribonucleic acid (DNA) repair gene encoding the excision-repair cross-complementation group 1 (ERCC1) protein is known to predict the response to platinum-based chemotherapy. Our aim was to explore whether ERCC1 expression predicted tumor response and survival in patients with recurrent or metastatic cervical cancer treated via platinum-based chemotherapy. We analyzed 32 such patients. ERCC1 expression was assessed immunohistochemically in pretreatment biopsy samples. Of the 32 patients, 13 (40.6%) were ERCC1 high. ERCC1-low patients exhibited a significantly higher response rate (73.7%) than did others (15.4%). The median progression-free survival differed significantly by ERCC1 status, being 135 days in ERCC1-high and 242 days in ERCC1-low patients (hazard ratio, 2.428; 95% confidence interval, 1.145–5.148, P = .032). Overall survival was significantly longer in ERCC1-low (617 days) than in ERCC1-high (320 days) patients (hazard ratio, 2.322; 95% confidence interval, 1.051–5.29; P = .037). Thus, pretreatment ERCC1 expression status can be used to predict tumor response and survival of patients with recurrent or metastatic uterine cervical cancer receiving platinum-based chemotherapy. |
format | Online Article Text |
id | pubmed-5758255 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-57582552018-01-29 ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy Ryu, Hyewon Song, Ik-Chan Choi, Yoon-Seok Yun, Hwan-Jung Jo, Deog-Yeon Kim, Jin Man Ko, Young Bok Lee, Hyo Jin Medicine (Baltimore) 5700 The deoxyribonucleic acid (DNA) repair gene encoding the excision-repair cross-complementation group 1 (ERCC1) protein is known to predict the response to platinum-based chemotherapy. Our aim was to explore whether ERCC1 expression predicted tumor response and survival in patients with recurrent or metastatic cervical cancer treated via platinum-based chemotherapy. We analyzed 32 such patients. ERCC1 expression was assessed immunohistochemically in pretreatment biopsy samples. Of the 32 patients, 13 (40.6%) were ERCC1 high. ERCC1-low patients exhibited a significantly higher response rate (73.7%) than did others (15.4%). The median progression-free survival differed significantly by ERCC1 status, being 135 days in ERCC1-high and 242 days in ERCC1-low patients (hazard ratio, 2.428; 95% confidence interval, 1.145–5.148, P = .032). Overall survival was significantly longer in ERCC1-low (617 days) than in ERCC1-high (320 days) patients (hazard ratio, 2.322; 95% confidence interval, 1.051–5.29; P = .037). Thus, pretreatment ERCC1 expression status can be used to predict tumor response and survival of patients with recurrent or metastatic uterine cervical cancer receiving platinum-based chemotherapy. Wolters Kluwer Health 2017-12-22 /pmc/articles/PMC5758255/ /pubmed/29390553 http://dx.doi.org/10.1097/MD.0000000000009402 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5700 Ryu, Hyewon Song, Ik-Chan Choi, Yoon-Seok Yun, Hwan-Jung Jo, Deog-Yeon Kim, Jin Man Ko, Young Bok Lee, Hyo Jin ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy |
title | ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy |
title_full | ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy |
title_fullStr | ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy |
title_full_unstemmed | ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy |
title_short | ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy |
title_sort | ercc1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758255/ https://www.ncbi.nlm.nih.gov/pubmed/29390553 http://dx.doi.org/10.1097/MD.0000000000009402 |
work_keys_str_mv | AT ryuhyewon ercc1expressionstatuspredictstheresponseandsurvivalofpatientswithmetastaticorrecurrentcervicalcancertreatedviaplatinumbasedchemotherapy AT songikchan ercc1expressionstatuspredictstheresponseandsurvivalofpatientswithmetastaticorrecurrentcervicalcancertreatedviaplatinumbasedchemotherapy AT choiyoonseok ercc1expressionstatuspredictstheresponseandsurvivalofpatientswithmetastaticorrecurrentcervicalcancertreatedviaplatinumbasedchemotherapy AT yunhwanjung ercc1expressionstatuspredictstheresponseandsurvivalofpatientswithmetastaticorrecurrentcervicalcancertreatedviaplatinumbasedchemotherapy AT jodeogyeon ercc1expressionstatuspredictstheresponseandsurvivalofpatientswithmetastaticorrecurrentcervicalcancertreatedviaplatinumbasedchemotherapy AT kimjinman ercc1expressionstatuspredictstheresponseandsurvivalofpatientswithmetastaticorrecurrentcervicalcancertreatedviaplatinumbasedchemotherapy AT koyoungbok ercc1expressionstatuspredictstheresponseandsurvivalofpatientswithmetastaticorrecurrentcervicalcancertreatedviaplatinumbasedchemotherapy AT leehyojin ercc1expressionstatuspredictstheresponseandsurvivalofpatientswithmetastaticorrecurrentcervicalcancertreatedviaplatinumbasedchemotherapy |